Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KDM4A | O75164 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6231378 | 0.89 | KDM4E (0.35) | GAATP53KDM4EALDH1A1MAPT | |
| SCHEMBL10752054 | 0.84 | NPC1 (0.34) | NPC1GAATP53POLBL3MBTL1 | |
| SCHEMBL6234040 | 0.80 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL6237163 | 0.75 | GAA (0.42) | NPC1GAATP53L3MBTL1LMNA | |
| SCHEMBL10099636 | 0.73 | L3MBTL1 (0.44) | GAATP53POLBL3MBTL1LMNA | |
| SCHEMBL6553757 | 0.72 | MEN1 (0.43) | L3MBTL1KMT2AMEN1ALDH1A1TDP1 | |
| SCHEMBL27755696 | 0.71 | TP53 (0.34) | GAATP53POLBL3MBTL1LMNA | |
| SCHEMBL6232620 | 0.70 | ALDH1A1 (0.31) | GAAKDM4EALDH1A1MAPT | |
| SCHEMBL6232469 | 0.69 | ADRA2C (0.32) | — | |
| SCHEMBL10714123 | 0.68 | PRKCD (0.42) | GAATP53L3MBTL1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3639821-B1 | CARCINOGENESIS INHIBITOR | NAT CANCER CT (JP) | 2024-08-28 | — | — | EP | disclosed |
| CN-110740729-B | Carcinogenesis inhibitor | 国立研究开发法人国立癌症研究中心 | 2023-05-16 | — | — | CN | disclosed |
| US-20230012898-A1 | LAMINATE, DISPLAY DEVICE, AND ORGANIC ELECTROLUMINESCENT DISPLAY DEVICE | FUJIFILM CORPORATION (JP) | 2023-01-19 | — | — | US | disclosed |
| US-11464762-B2 | Carcinogenesis inhibitor | NATIONAL CANCER CENTER (JP) | 2022-10-11 | — | — | US | disclosed |
| US-20220223825-A1 | LAMINATE AND ORGANIC ELECTROLUMINESCENT DISPLAY DEVICE | FUJIFILM CORPORATION (JP) | 2022-07-14 | — | — | US | disclosed |
| US-20200276163-A1 | CARCINOGENESIS INHIBITOR | NATIONAL CANCER CENTER (JP) | 2020-09-03 | — | — | US | disclosed |
| EP-3639821-A1 | CARCINOGENESIS INHIBITOR | National Cancer Center (JP) | 2020-04-22 | — | — | EP | disclosed |
| CN-110740729-A | Carcinogenesis inhibitor | 国立研究开发法人国立癌症研究中心 | 2020-01-31 | — | — | CN | disclosed |
| EP-1243261-B1 | Use of a hydantoin derivative in a pharmaceutical composition against hypoalbuminaemia | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2005-04-27 | — | — | EP | disclosed |
| CN-1197572-C | Hypoalbuminemia improvement agent | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2005-04-20 | — | — | CN | disclosed |
| US-20020147228-A1 | AGENT FOR HYPOALBUMINAEMIA | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2002-10-10 | — | — | US | disclosed |
| CN-1371687-A | Hypoalbuminemia improvement agent | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2002-10-02 | — | — | CN | disclosed |
| EP-1243261-A1 | Use of a hydantoin derivative in a pharmaceutical composition against hypoalbuminaemia | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2002-09-25 | — | — | EP | disclosed |
| US-6451831-B1 | TREATMENT WITH HYDANTOIN DERIVATIVE | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2002-09-17 | — | — | US | disclosed |
| US-6251929-B1 | ADMINISTERING TO A PATIENT A HYDANTOIN DERIVATIVES AND SALTS AS THERAPEUTIC AND PREVENTIVE AGENTS FOR INTRACTABLE VASCULITIS SUCH AS MALIGNANT RHEUMATOID ARTHRITIS(MRA), PERIARTERITIS NODOSA, WEGENER'S GRANULOMATOSIS ETC. | NIPPON ZOKI PHARMACEUTICALS CO., LTD. (JP) | 2001-06-26 | — | — | US | disclosed |
| EP-0780125-B1 | Use of hydantoin derivatives for the preparation of a medicament for the treatment of dieases associated with the presence of active oxygen and free radicals | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2001-04-18 | — | — | EP | disclosed |
| US-6197806-B1 | USING A HYDANTOIN DERIVATIVE | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2001-03-06 | — | — | US | disclosed |
| EP-1018339-A1 | Therapeutic agent for intractable vasculitis | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2000-07-12 | — | — | EP | disclosed |
| CN-1159324-A | Active oxygen, free radical scavenger | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 1997-09-17 | — | — | CN | disclosed |
| EP-0780125-A2 | Pharmaceutical composition containing a hydantoin derivative and use of said derivative | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 1997-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11464762-B2 | Carcinogenesis inhibitor | APC, MKI67, HRAS | NPC1 175/4885GAA 3618/4885TP53 24/4885 |
| US-20020147228-A1 | AGENT FOR HYPOALBUMINAEMIA | ALB, TTR, SERPINA6 | NPC1 1939/4885GAA 2392/4885TP53 2399/4885 |
| US-20200276163-A1 | CARCINOGENESIS INHIBITOR | APC, MKI67, HRAS | NPC1 175/4885GAA 3618/4885TP53 24/4885 |
| US-20230012898-A1 | LAMINATE, DISPLAY DEVICE, AND ORGANIC ELECTROLUMINESCENT DISPLAY DEVICE | EPCAM, ICAM1, STRA6 | NPC1 3317/4885GAA 3289/4885TP53 3749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.